New combo therapy targets hard-to-treat lymphoma

NCT ID NCT07059650

Recruiting now Disease control Sponsor: Dizal Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called DZD8586 combined with standard treatments for diffuse large B-cell lymphoma (DLBCL), a fast-growing blood cancer. It involves 150 adults whose cancer is either newly diagnosed or has returned after initial therapy. The goal is to see if the combination shrinks tumors and to check for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Anhui Provincial Cancer Hospital
RECRUITING

Hefei, China
Guangdong Provincial People's Hospital
RECRUITING

Guangzhou, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, China
Linyi Cancer Hospital
RECRUITING

Linyi, China
Peking University Third Hospital
RECRUITING

Beijing, China
Shanxi Cancer Hospital
RECRUITING

Taiyuan, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, China
The First Affiliated Hospital of Xi'an Jiaotong University
RECRUITING

Xi'an, China
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITING

Hangzhou, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, China
Zhujiang Hospital of Southern Medical University
RECRUITING

Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.